[Sleep disorders in patients with dementia in Parkinson's disease].
Dementia and psychotic disorders are frequent complications of Parkinson's disease (PD). They occurred in 40-60% of the cases. These complications are often accompanied by sleep disorders which also are non-motor presentations of PD. The objectives of the present study were 1) the assessment of correlations of daily sleepiness and behavioral disturbances during the fast sleep phase (REM-phase) with cognitive impairment and hallucinations; 2) the comparison of evaluation of sleep disorders in PD with questionnaires or polysomnographic study; 3) the assessment of the effect of galantamine on sleep disorders. Using a battery of scales (MMSE, FAB, ESS, PDSS) and polysomnographic study, we evaluated a state of sleep and cognitive functions in 26 PD patients with dementia before and after treatment with galantamine. The results obtained demonstrated the significant negative correlations of the severity of sleep disorders (excessive day sleepiness and disturbances of behavior in REM-phase) with hallucinations and cognitive disorders. Galantamine improved the quality of night sleep (the restoration of structure, decrease of fragmentation), decreased the severity of behavior disorders during REM-phase and day sleepiness along with changes in the intensity of cognitive disturbances and hallucinations.
I V
IV
Litvinenko
I V
IV
Krasakov
O V
OV
Tikhomirova
D000368:Aged; D003704:Dementia / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications*; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D012895:Sleep, REM
D005702:Galantamine